Table 1.

Characteristics in the PIVUS and ULSAM studies

VariablePIVUSULSAM
No. of subjects687360
Women, n (%)335 (49)0
Age, yr70.1±0.1577.5±0.77
eGFR at baseline, ml/min per 1.73 m289±1776±15
eGFR at 5-yr follow-up, ml/min per 1.73 m264±1651±18
Urinary albumin-to-creatinine ratio, mg/gNA20±45
Body mass index, kg/m227.3±4.126.2±3.3
Systolic BP, mmHg149±21150±21
LDL, mg/dl131±35135±31
HDL, mg/dl58±1550±12
Fasting blood glucose, mmol/l5.3±1.55.8±1.4
CKD stage, n (%)
 1, eGFR≥90 ml/min per 1.73 m2347 (50.5)62 (17.2)
 2, eGFR=60–89 ml/min per 1.73 m2305 (44.4)242 (67.2)
 3, eGFR=30–59 ml/min per 1.73 m235 (5.1)56 (15.6)
 4, eGFR=15–29 ml/min per 1.73 m20 (0)0 (0)
 5, eGFR<15 ml/min per 1.73 m20 (0)0 (0)
Statin treatment, n (%)112 (16)64 (18)
Other lipid-lowering treatment, n (%)7 (1)NA
Smoking, n (%)62 (9)19 (5)
Cardiovascular disease, n (%)112 (16)59 (16)
Diabetes, n (%)74 (11)40 (11)
Oral antidiabetic drugs, n (%)44 (6)2 (0.5)
Insulin treatment, n (%)13 (2)19 (5)
Diuretics, n (%)86 (13)48 (13)
β-blockers, n (%)142 (21)74 (21)
Calcium antagonists, n (%)74 (11)52 (14)
Angiotensin-converting enzyme inhibitors, n (%)62 (9)58 (16)
Angiotensin receptor blockers, n (%)60 (9)0 (0)
Use of nonsteroidal anti-inflammatory drugs, n (%)27 (4)18 (5)
  • Normally distributed continuous variables are presented as mean±SD and categorical variables as n (%). PIVUS, the Prospective Investigation of the Vasculature in Uppsala Seniors Study; ULSAM, the Uppsala Longitudinal Study of Adult Men; NA, not available.